Perspective Therapeutics
CATX
38 hedge funds and large institutions have $3.93M invested in Perspective Therapeutics in 2020 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
0% more funds holding
Funds holding: 38 → 38 (0)
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
0.06% less ownership
Funds ownership: 1.05% → 0.98% (-0.06%)
0% less capital invested
Capital invested by funds: $3.94M → $3.93M (-$9.99K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$265K |
| 2 |
VF
Virtu Financial
New York
|
+$52.1K |
| 3 |
Creative Planning
Overland Park,
Kansas
|
+$51.3K |
| 4 |
Squarepoint
New York
|
+$43.6K |
| 5 |
AAS
Avantax Advisory Services
Dallas,
Texas
|
+$32.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$370K |
| 2 |
EI
EAM Investors
Solana Beach,
California
|
-$172K |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$10.9K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$10.5K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$7K |
CATX Hedge Fund Activity: Q3 2020 in Review
38 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Perspective Therapeutics (CATX) for Q3 2020, worth a combined $3.93M — down 0.25% from $3.94M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new CATX positions and 2 closed out — a net gain of 2 holders — while 6 added to existing stakes and 6 trimmed.
The largest buyer was Vanguard Group, adding an estimated $265K. The largest seller was Renaissance Technologies, cutting an estimated $370K.
- 38 institutional investors held Perspective Therapeutics (CATX) as of Q3 2020, unchanged from Q2 2020.
- Funds reported $3.93M of Perspective Therapeutics stock for Q3 2020, down 0.25% quarter-over-quarter.
- 4 funds opened new Perspective Therapeutics positions in Q3 2020 and 2 closed out, a net change of +2 holders.
- The largest Perspective Therapeutics buyer in Q3 2020 was Vanguard Group, an estimated $265K added.
- The largest Perspective Therapeutics seller in Q3 2020 was Renaissance Technologies, an estimated $370K sold.
Based on aggregated 13F filings for Q3 2020.